INTRODUCTION
VEGF (vascular endothelial growth factor) is best known as a hypoxia-inducible, secreted protein that activates receptor protein tyrosine kinases on vascular endothelial cells to stimulate angiogenesis. But that is not all this important factor does. VEGF has also controls neurogenesis in the sub-granular layer of adult dentate gyrus, and correspondingly, memory formation, the progressive failure of which is perhaps one of the most distressing characteristics of Alzheimer's disease (AD) [1] .
A possible involvement of VEGF in AD is suggested by the VEGF-A gene being one of several genes upregulated, along with Aβ 1−42 accumulation in AD brains but not in age-matched normal brains [2, 3] . Additionally, Kalaria and colleagues [4] found prominent immunoreactive VEGF in clusters of reactive astrocytes on blood vessel walls and in diffuse perivascular deposits of Aβ 1−42 in the neocortices of AD brains, but not in age-comparable normal brains. Because of this correlation between VEGF expression and AD, it is important to find out what causes astrocytes to synthesize VEGF, as this might have important consequences in an AD brain.
The VEGF expression in the AD brain could be caused by astrocytes reacting to local hypoxia,resulting from accumulation of perivascular Aβ 1−42 , with the resulting stabilization of hypoxia-inducible factor (HIF)-1α protein and the nuclear translocation of HIF-1α · HIF-1β (ARNT1 or aryl hydrocarbon receptor nuclear translocator1) to stimulate VEGF-A gene expression. Alternatively accumulating Aβ 1−42 peptides might directly stimulate astrocytes independently of hypoxia to make VEGF. An Aβ 1−42 -related action is suggested by the VEGF immunoreactivity in astrocytes and microglia and neovascularization that appear a week after injecting Aβ 1−42 into the normal rat hippocampus [5] . However, this week-long delay suggests that the injected Aβ 1−42 did not directly stimulate VEGF-A expression in the hippocampal glial cells -the VEGF expression required some Aβ 1−42 -induced mediator(s). This could have been the proinflammatory cytokines that are well known to be produced by activated glial cells in the Aβ 1−42 -accumulating AD brain [6, 7] .
Thus, the evidence for Aβ 1−42 being able to stimulate directly VEGF expression is equivocal. Park and Chae [8] have reported that Aβ 1−42 did not stimulate HN33 mouse neuroblastoma cells and neonatal rat astrocytes to make VEGF. On the other hand, Soucek and coworkers [9] , working with cultured nerve cell lines and primary cortical neurons, reported that Aβ 1−42 stabilized HIF-1α, which in turn induced the formation of HIF1-α · HIF1-β, the heterodimeric transcription factor that stimulates the expression of the VEGF-A gene [10] [11] [12] [13] [14] [15] [16] [17] [18] . To resolve this contradictory issue, we have tested the VEGF-stimulating abilities of Aβ 25−35 and of proinflammatory cytokine(s) with a culture model that is directly relevant to the adult human brain; that is, phenotypically normal, proliferatively quiescent astrocytes from adult human temporal lobe cerebral cortex (NAHAs, normal adult human astrocytes). We will show that the synthetic peptide Aβ 25−35 , an Aβ 1−42 surrogate whose physical and biological features it preserves [19] stabilizes HIF-1αprotein without affecting HIF-1β expression and stimulates the nuclear translocation of the HIF-1α · HIF-1β heterodimer, its binding to HRE DNA, the expression of VEGF-A mRNA splice variants, and the secretion of VEGF-A 165 , the major splice variant synthesized in NAHAs. We will also show that the mixture of three proinflammatory cytokines notoriously produced in AD brains, namely IL-1β+IFN-γ+TNF-α, which we have previously shown to strongly stimulate NAHAs to make nitric oxide (NO) [20] [21] [22] [23] , not only synergistically stabilizes HIF-1α protein but, unlike Aβ 25−35 , also increases HIF-1β expression and consequently more strongly stimulates VEGF-A 165 secretion.
MATERIALS AND METHODS

Isolation and culture of phenotypically normal NAHAs
NAHAs were isolated from temporal lobe cerebral cortex tissue fragments of five male patients (range: 18-38 years) with perforating head injuries due to motorcycle accidents who underwent neurosurgery immediately. The cells were promptly cultured and propagated as previously described in full detail [24] [25] [26] [27] . The cells of these pure cultures only expressed astrocytespecific markers such as glial fibrillary acid protein and glutamine synthase. None of the cells expressed neuronal (enolase), oligodendrocytes (galactocerebroside), microglia (CD-68), or endothelial cells (factor VIII) markers. These astrocytes proliferated slowly without added growth factors in 90% (v/v) Ham's F-12/MCDB 153 medium and 10% (v/v) heat-inactivated fetal bovine serum. They stopped growing upon reaching confluence. Under both proliferating and nonproliferating conditions the NAHAs steadily expressed their characteristic astrocyte markers -they were phenotypically "locked-in". But serum remained a necessary component of the medium and withdrawing it caused the astrocytes to self-destruct by apoptosis. The astrocytes of confluent, proliferatively quiescent cultures started cycling again when subcultured. Only astrocytes from the fourth to the eighth subculture were used because the response of the cells to proinflammatory cytokines or Aβ 25−35 became erratic with further subculturing.
Experimental protocol
Since astrocytes do not normally proliferate in the adult human brain, we studied the effects on VEGF-A production and release by Aβ 25−35 , the reversedsequence Aβ 35−25 or proinflammatory cytokine(s) using confluent, proliferatively quiescent, pure NAHA cultures [24] [25] [26] [27] . At "0-h", some cultures served as untreated controls, while others were treated with (i) 20 µM of either Aβ 25−35 or the inactive Aβ 35−25 (Bachem, Bubendorf, Switzerland) or (ii) IL-1β (20 ng ml), TNF-α (20 ng ml), and IFN-γ (70 ng ml) (all from PeproTech EC Ltd., London, UK) either administered individually or in pairs or as a three cytokine mixture (the CM-trio). These concentrations were previously shown to be non-cytotoxic and when administered together in a trio to potently stimulate MAP kinases and NO production in NAHAs [24] [25] [26] [27] . Cultures were sampled between 18 h and 72 h after the onset of each treatment.
Expression of HIF-1α, HIF-1β (ARNT1), and VEGF-A splice variants' mRNAs assessed via RT-PCR
RNA was extracted using a total RNA extraction kit, Perfect Pure TM (5PRIME, Eppendorf Italia, Milan, Italy), according to the manufacturer's instructions. The RNA quality was corroborated via electrophoresis of 1 µg of total RNA in 1% agarose gel 20 µg/ml ethidium bromide for 1 h at 90 V. Reverse transcription of 0.5 µg aliquots of total mRNA was carried out using the Transcriptor High Fidelity TM cDNA Synthesis Sample Kit (Roche Diagnostics, Milan, Italy) according to the manufacturer's directions. Briefly, mRNA aliquots (0.5 µg) were mixed with 2.5 µg oligo (dT)-18 primers, heated for 10 min at 65
• C and then cooled on ice. To the tube containing the template primer-mix, Transcriptor High Fidelity Reverse Transcriptase Reaction Buffer 1X 8 mM MgCl 2 , 20 U Protector RNAse Inhibitor, deoxynucleotide mix 1 mM each, DTT 5 mM, 10 U Transcriptor High Fidelity Reverse Trascriptase were then added. The reaction was next incubated for 30 min at 45
• C and for 5 min at 85 • C. Specific primers for human VEGF-A and glyceraldehyde-3-phosphate dehydrogenase (GADPH) were those previously reported [28] . Specific primers for human HIF-1α and HIF-1β (ARNT1) were designed using Primer3 software (version 0. • C for 30 s, 60
• C for 1 min, and 72
• C for 1 min; HIF-1α and GADPH, through 23 and 22 cycles, respectively, of 94
• C for 30 s, 55
• C for 1 min; HIF-1β, through 25 cycles of 94
• C for 30 s, 60
• C for 10 s, and 72
• C for 20 s. The final PCR products were electrophoresed on 2% agarose gel in 1X tris-borate ED-TA buffer for 90 min at 90 V, stained by stirring with Syto 60 1:20000 in RNAse-DNAse-free water for 45 min, scanned in an Odissey TM infrared imaging system (Licor Biosciences, Inc.; Lincoln, NE), and the integrated intensity of each specific band accurately quantified (in arbitrary units) using proprietary software. To permit semi-quantitative analysis GAPDH was utilized as an internal control. Sequencing analyses validated the identities of the PCR DNA products fragments (not shown).
Western immunoblotting
At chosen time points, control and treated NAHAs were scraped into cold PBS, sedimented at 200 g for 10 min, and homogenized in T-PER TM tissue protein extraction reagent (Pierce, Rockford, IL) containing a complete EDTA-free protease inhibitor cocktail (Roche). The protein contents of the samples were determined according to Bradford [29] using BSA as standard. Equal amounts (10-20 µg) of protein from the samples were heat-denatured for 10 min at 70
• C in an appropriate volume of 1X NuPAGE LDS Sample Buffer supplemented with 1X NuPAGE Reducing Agent (Invitrogen). The samples were next loaded on a NuPAGE Novex 10% Bis-Tris polyacrylamide gel (Invitrogen). After electrophoresis in NuPAGE MOPS SDS Running Buffer using the Xcell SureLock TM Mini-Cell (Invitrogen) (50 min run-time at 200 V constant), proteins were blotted onto nitrocellulose membranes (0.2 µm; Pall Italia, Milan, Italy). To ensure efficient and reproducible binding to the membrane, transfer proceeded under low power (30 V constant) for 1-h in 1X NuPAGE Transfer Buffer containing 10% methanol and 0.1% NuPAGE antioxidant. Membranes were probed with rabbit anti-human VEGF-A IgG polyclonal antibody (Santa Cruz Biotechnology; Heidelberg, Germany) or rabbit anti-HIF-1α antibody (Novus Biologicals, Littleton, CO) or anti-HIF-1β antibody (Santa Cruz Biotechnology) or anti-lamin B1 antibody (Santa Cruz Biotechnology) at a final dilution of 1 µg ml. Subsequent processing was carried out as previously detailed [24] [25] [26] [27] . Lamin B1 was used as the loading control.
ELISA assay of VEGF-A
Cell-conditioned growth media were taken at 0-h, 18-h, 24-h, 48-h, and 72-h after the onset of exposure of NAHA cultures to each individual cytokine or cytokine pairs, CM-trio, or Aβ 25−35 or Aβ 35−25 , and stored at −80
• C to be subsequently assayed for their VEGF-A content. This was done with a specific commercial ELISA kit (PeproTech). The tests were carried out according to the instructions of the manufacturer. The sensitivity of the assays for VEGF-A was 16 pg ml.
ELISA for HIF-1α transcriptional activity
NAHAs nuclear proteins were extracted using a kit from Panomics (Fremont, CA) and carried out as suggested by the manufacturer. Protein content was determined by the Bradford protein assay kit (Bio-Rad; Milan, Italy). An ELISA kit from Panomics was used to assess the hypoxia response element (HRE) DNA binding of the nuclear-extracted HIF-1α transcription factor. Briefly, to form the HIF-1α/HRE DNA complex, 40 µl of binding buffer master mix were incubated with 10 µl of sample nuclear extract (0.5 µg/ml) in the sample plates for 30 min at room temperature. From each well of the sample plate, 45 µl were then transferred to the assay plate. To capture the HIF-1α/HRE DNA complex, the assay plate was washed three times with the provided buffer and the samples were incubated with a primary antibody against HIF-1α for 1 h at room temperature. After washing and incubation with the secondary antibody, colorimetric signals were then developed by adding a TMB substrate solution to each well, and read with a Multiskan TM (Labsystems, Finland) spectrophotometer at 450 nm.
Statistics
The data were analyzed using SigmaStat 3.5 Advisory Statistics for Scientists (Systat Software, Richmond, CA). For RT-PCRs, data were normalized to GADPH and next analyzed by one-way ANOVA. For immunoblotting, data were normalized to lamin B1 and next analyzed by one-way ANOVA. Post hoc HolmSidak's test was used for multiple pair-wise comparisons. Null hypotheses were rejected when P > 0.05.
RESULTS
VEGF-A protein secreted into the NAHA-conditioned growth medium
We could detect small amounts of VEGF-A released into the medium by the untreated NAHAs (Fig. 1A,B) . When administered separately, IL-1β, TNF-α, or IFN-γ did not significantly change the basal 72 h VEGF-A secretion (P > 0.05 vs. controls [None]) (Fig. 1A) . Of the cytokine pairs tested only the TNF-α+IFN-γ could increase VEGF-A secretion (P < 0.001 vs. controls). However, the CM-trio (IL-1β+IFN-γ+TNF-α) was the strongest stimulator of VEGF-A secretion by 72 h (P < 0.001 or < 0.002 vs. controls and all other cytokine[s] treatments; Fig. 1A ). Aβ 25−35 by itself also significantly, though less strongly, stimulated VEGF-A secretion by 72 h (P < 0.001 vs. controls) (Fig. 1A) . By contrast, the reverse-sequence Aβ peptide, Aβ 35−25 , was ineffective (P > 0.05 vs. controls), which established the specificity of the stimulatory action of Aβ 25−35 (Fig. 1A) .
The timings of the VEGF responses to Aβ 25−35 and the CM-trio are shown in Fig. 1B . The extracellular VEGF-A level stimulated by the CM-trio started rising after 18 h, and the level stimulated by Aβ 25−35 started rising after 24 h and then both rose steadily thereafter (Fig. 1B) . According to the areas under the three secretion curves in Fig. 1B , the total amount of VEGF-A secreted between 0 and 72 h by the CM-trio-stimulated NAHAs was 289% higher than the amount secreted by untreated cells and that by the Aβ 25−35 -treated NAHAs was 148% higher than that secreted by untreated cells (in both instances P < 0.05 vs. untreated controls) ( Table 1) . Then again, the total amount of VEGF-A secreted by the CM-trio-treated NAHAs was 36% more than the amount secreted by the Aβ 25−35 -treated NAHAs and this difference was significant (P < 0.05) ( Table 1) . 1406 ± 232 + 148% vs. None − 36% vs. CM-trio P < 0.05 P < 0.05 * Total VEGF-A secretion was obtained via the integral calculus of the surface areas (in mm 2 ) under the secretion curves in Fig. 1B . Points in the curves are expressed in pg ml −1 of the means ± SEM of the samples, each assayed in triplicate, from 25 untreated (None) cultures and 5-7 Aβ 25−35 -or CM-trio-treated cultures. One-way ANOVA analysis of the complete data set provided an F value of 16.323 (P < 0.001). * * Pair-wise comparisons were carried out using post-hoc Holm-Sidak's test. , F = 14.132, P < 0.001; CM-trio, F = 39.526, P < 0.001; pair-wise comparisons with post hoc Holm-Sidak's test, * P < 0.05 vs. 0-h levels; * * P < 0.05 vs. 18-h levels; * * * P < 0.05 vs. 24 h levels; * * * * P < 0.05 vs. 48 h levels. CM-trio-induced increases in secreted VEGF-A at both 24 h and 72 h were significantly higher (t test, P < 0.05) than the surges caused by Aβ 25−35 . For the total 0-to-72-h secretion of VEGF-A by the NAHAs see Table 1 .
Thus, VEGF-A secretion by NAHAs was strongly increased by either the CM-trio or Aβ 25−35 experimental treatments, but we did not know what VEGF-A splice variants were secreted. To find this out we analyzed the proteins in NAHAs lysates via immunoblotting.
VEGF-A splice variants in NAHAs lysates
The NAHAs expressed three protein splice variants of VEGF-A, i.e., VEGF-A 121 , VEGF-A 165 , and VEGF-A 189 (Fig. 2A) . But, as expected, production of one of them, in this case VEGF-A 165 , predominated. Indeed, to measure VEGF-A 189 and VEGF-A 121 in the immunoblots, it was necessary to load 4 to 5-fold more NAHAs' protein lysate than the usual 10-20 µg into the gel lanes. Since about three quarters of the total VEGF-A protein in the NAHAs lysates was VEGF-A 165 , we focused our attention on it ( Fig. 2A) . Thus, our immunoblot studies showed that the intracellular VEGF-A 165 protein level fell slightly but not significantly (−10% by 48 h vs. 0 h levels; P > 0.05) in Aβ 25−35 -treated NAHAs, while it rose slightly, but again not significantly (+25% by 48 h vs. 0 h levels; P > 0.05) in CM-trio-treated NAHAs (Fig. 2B) . Thus, nearly all of the newly produced VEGF-A 165 was rapidly released by NAHAs into the medium and not significantly stored in the cytoplasm.
VEGF-A splice variant mRNAs in NAHAs
Alternative splicing of the VEGF-A RNA transcript at the gene's exons 6 and 7 is known to produce several different mRNAs [30, 31] . As expected from the immunoblots, we found, using RT-PCR, that untreated NAHAs did indeed express three VEGF-A mRNA transcripts corresponding to the above mentioned three VEGF-A isoforms (Fig. 3) .
We found in Aβ 25−35 -exposed NAHAs that by 72 h the major VEGF-A 165 and the minor VEGF-A 189 mRNAs were significantly (P < 0.05) upregulated vs. basal (0 h) values, whereas the minor VEGF-A 121 -encoding mRNA did not undergo statistically significant (P > 0.05) changes between 24 h and 72 h (Fig. 3A) . In the CM-trio-exposed NAHAs, the levels of the VEGF-A 189 , VEGF-A 165 , and VEGF-A 121 mRNAs were all significantly increased (P < 0.05) over basal (0 h) levels between 24 h and 48 h to fall thereafter (Fig. 3B) . Thus, both Aβ 25−35 and the CM-trio significantly stimulated the mRNA expression of the major splice variant, VEGF-A 165 .
HIF-1α and HIF-1β (ARNT1) mRNA and protein expression in NAHAs
We then asked whether Aβ 25−35 and the CM-trio could stimulate VEGF-A 165 like hypoxia by simply stabilizing HIF-1α and thus enabling the formation of HIF-1α · HIF-1β (ARNT1) transcription factor heterodimer [10] [11] [12] [13] 32, 33] or did they stimulate the HIF-1α and/or HIF-1β gene or directly the VEGF-A gene.
Neither Aβ 25−35 nor the CM-trio significantly changed the basal HIF-1α (Fig. 4A) or HIF-1β mRNA levels (Fig. 5A) in the NAHAs. Although they did not affect the HIF-1α gene expression, they stimulated a significant surge of HIF-1α protein between 0 h and 48 h (Fig. 4B) . However, the CM-trio, but not Aβ 25−35 , also significantly increased the HIF-1β protein level in NAHAs at 24 h and 48 h (Fig. 5B) . Thus, while Aβ 25−35 stabilized only the O 2 -sensitive HIF-1α protein, the CM-trio stabilized and augmented the levels of both the HIF-1α and HIF-1β transcription factors in the 'normoxic' NAHAs.
HIF-1α nuclear translocation and DNA binding at HRE sites in NAHAs
We then found that Aβ 25−35 or the CM-trio significantly stimulated the nuclear translocation and HRE DNA binding of the HIF-1α, and therefore the HIF-1α · HIF-1β heterodimer, in the NAHAs (Fig. 6) . The nuclear HRE DNA-bound HIF-1α level peaked around 24 h with the Aβ 25−35 -driven translocation being slightly slower than the CM-trio-driven translocation (Fig. 6 ). But then the nuclear levels of HIF-1α in both the Aβ 25−35 -and CM-trio-treated NAHAs dropped rapidly to the starting level by 48 h. Thus, the reason for the CM-trio's superior ability to stimulate VEGF-A 165 production and secretion, as shown in Fig. 1 , could consist in the ability of the CM-trio to stabilize and hence increase both HIF-1α and HIF-1β levels (Figs 4B and 5B) and, therefore, boost the flow of VEGF-A gene-activating HIF-1α · HIF-1β het- erodimers into the nucleus.
DISCUSSION
The present results obtained with relatively 'normoxic' NAHA cultures indicate that the VEGF-A production by astrocytes in AD brains, but not age-matched normal brains [6] , need not be due just to hypoxia [4, [34] [35] [36] , but also to the direct actions of Aβ peptides and the ensemble of cytokines accumulating in the inflammatory environment of these brains. Yet these agents acted like hypoxia by stimulating the formation and nuclear translocation of the HIF-1α · HIF-1β heterodimers. Surprisingly, unlike the Aβ 1−42 surrogate Aβ 25−35 , none of the three members of the cytokine trio could by itself significantly stimulate VEGF-A production by cultured NAHAs -they had to work together to induce the strongest stimulus of VEGF-A production and release. However, the TNF-α+IFN-γ pair did stimulate VEGF-A release, though less strongly than the trio. In previous work by Argaw et al. [37] , a differ- ent cytokine pair, for example IL-1β+IFN-γ was found to stimulate VEGF-A secretion by normal fetal human astrocytes more efficiently than either IL-1β or IFN-γ given individually (the CM-trio was not tested). Even IL-1β by itself was a weaker yet effective stimulator in such cells. The divergence of our present findings from those of Argaw et al. [37] clearly implies that the modulation of VEGF-A production on the part of proinflammatory cytokines changes significantly as the normal fetal human astrocyte matures into an adult cell. Hence, caution should be advisable in extrapolating the cytokine-induced stimulatory mechanisms from fetal to adult human astrocytes.
Thus, both Aβ 25−35 and the CM-trio did stimulate VEGF-A 165 transcript expression and increased the formation and nuclear translocation of HIF-1α · HIF-1β heterodimers. But the question arises as to how Aβ 25−35 and the CM-trio could have stabilized HIF-1α to produce HIF-1α · HIF-1β heterodimers in our 'normoxic' NAHA cultures. One possibility might be the strong stimulation by the cytokine ensemble and by Aβ 25−35 of the expression of the NOS-2 (NO synthase-2) gene and production of the proline hydroxylaseinhibiting NO [24, 25, 38, 39] . This NO certainly would stabilize HIF-1α and enable HIF-1α · HIF-1β formation [40] [41] [42] [43] , but it happens too late [24, 25] . Indeed, the nuclear translocation of HIF-1α · HIF-1β to the HRE DNA sites in the NAHAs peaked at 24 h, not 72 h, as did the NO production in NAHA cultures (data not shown; [24, 25] ). Clearly, it remains to be discovered how Aβ 25−35 by itself and the synergistically acting members of the CM-trio stabilized HIF-1α in NAHAs. Nevertheless, our results obtained with the cultured NAHAs could explain the delayed VEGF response of rat hippocampal astrocytes to injected Aβ 1−42 reported by Zand et al. [5] -they had to wait for the injected Aβ 1−42 to induce microglia to generate an inflammatory environment and release an effective cytokine ensemble [7, [20] [21] [22] [23] .
Finally, we should look at what an abnormal Aβ 1−42 -and cytokines-driven VEGF-A production might do in the proinflammatory environment of an AD brain. The release of angiogenic VEGF-A from the astrocytes of the neurobarrier-coupling units with their blood vesselattached end-feet [44, 45] would be expected in an AD brain to produce new blood vessels to reverse or at least minimize the Aβ 1−42 -induced vascular damage responsible for hypoxia, glucose shortages, breached blood-brain barrier and failing Aβ 1−42 drainage [33, [46] [47] [48] [49] [50] [51] . But it may not do so, because hypoxic endothelial cells in the hypoperfused regions of an AD brain downregulate their MEOX-2 homeobox gene and its GAX protein product [47, 52] . This causes the endothelial cells to upregulate the AFX1 forkhead transcription factor that downregulates their anti-apoptogenesis Bcl-XL gene by stimulating the BCL-6 transcriptional repressor [52, 53] . The downregulation of MEOX-2 homeobox gene and its GAX protein product also lowers the level of the Aβ 1−42 -clearing soluble LRP1 [47, 52] . Therefore, while the increased VEGF production in an AD brain would indeed stimulate angiogenesis, this could counterproductively produce dysfunctional blood vessels with endothelial cells unable to clear Aβ 1−42 and hyper-prone to apoptogenesis.
While VEGF-A is best known for its angiogenic action, it has only recently been found to operate as a major factor in the radial glial (astrocyte-like) cell/vascular-based stem cell niche in the sub-granular zone of the dentate gyrus [1, 34] . There it links angiogenesis and vascular endothelial cell-produced brain-derived neurotrophic factor (BDNF) and BDNFstimulated adult neurogenesis to continuously supply the new granular cells needed to start recording the memory of novel polymodal inputs from the entorhinal cortex [1, 54] . Therefore, the increased expression of VEGF-A by astrocytes in a normal brain or induced by Zand et al.'s [5] injection of Aβ 1−42 into rat brains might promote the survival and proliferation of neural progenitor cells, as indicated by the response of hippocampal neuronal progenitor cells to infusion of the protein into the lateral ventricles of adult rats [55] . But this may be unlikely in an AD brain with its elevated VEGF-A expression, as Waldau and Shetty [56] reported in their review of neural stem cells in AD brains that the AD pathology would prevent any VEGF-Astimulated immature granule cells from differentiating into mature granule cells.
In conclusion, these observations suggest that the expression of VEGF by astrocytes that has been shown to occur in AD brains, but not normal aging brains, is likely because of the astrocytes responding to local hypoxia due vascular damage by accumulating perivascular Aβ 1−42 , as well as to the direct actions of accumulating Aβ 1−42 and proinflammatory cytokines from activated microglia. The contribution of the VEGF to the development of AD remains to be shown, but we suggest that it is likely not trivial.
